Supplemental Figure 5B from Exposure–Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients
Year: 2023
Type: supplementary-materials
Abstract: Representative Individual Concentration versus Time Pharmacokinetic Profiles for Total or Unbound Flavopiridol Using Bolus (A) or Hybrid (B) Dosing Schemes.
Authors: Carl LaCerte, Vijay Ivaturi, Joga Gobburu, Jacqueline M. Greer, L. Austin Doyle, John J. Wright, Judith E. Karp, Michelle A. Rudek
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361886579